MANGALAM vs PGHL: Stock Comparison

Mangalam Drugs And Organics Limited vs Procter & Gamble Health Limited

Live data: 22 July 2026, 2:57 PM IST • Source: NSE and company filings

Procter & Gamble Health Limited is the larger company by market capitalisation. Procter & Gamble Health Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Mangalam Drugs And Organics Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MANGALAM is more favourable on 0 of 11 scored metrics and PGHL on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PGHL is the larger company
₹11,172 Cr vs ₹43 Cr
EPS
PGHL has higher earnings per share
₹196.64 vs ₹-28.05
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs -7.5%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs 0%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs -7.54%
Qtr Profit Growth
PGHL has stronger quarterly profit growth
54.6% vs -22,467%
ROE
PGHL has a higher ROE
61.6% vs -35.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANGALAMPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANGALAMPGHL
Live Price₹27.08₹6,737
Day Change-0.66%-0.63%
Volume25,3564,521
52-Week High₹95₹6,975
52-Week Low₹22.8₹4,707
Distance from 52W High-71.49%-3.41%

Valuation

MetricMANGALAMPGHL
Market Cap₹43 Cr₹11,172 Cr
P/E Ratio34.28x
P/B Ratio21.36x
EPS₹-28.05₹196.64
Book Value₹65.12₹316.01
Dividend Yield0%2.34%

Growth

MetricMANGALAMPGHL
Revenue Growth (TTM YoY)-7.5%19.1%
EPS Growth (TTM YoY)0%54.6%
Qtr Sales Growth-7.54%19.1%
Qtr Profit Growth-22,467%54.6%

Profitability & Leverage

MetricMANGALAMPGHL
ROE-35.2%61.6%
ROCE-14.3%83.5%
Net Margin-19.13%23.22%
Operating Margin-6.42%32.4%
Debt to Equity1.02x0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMANGALAMPGHL
Promoter Holding35.65%0%
FII Holding0.11% 0.21 pp6.33% 0.13 pp
DII Holding0%12.44% 1.23 pp
Public Holding64.24% 0.22 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Mangalam Drugs And Organics Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.